Launch week offerEnds in00h00m00s

annual Promonthly Pro

Marc Georges Jean Lallemant

Senior Researcher

Chiang Mai University

No Info

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Articles (15)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Ratchada Cressey

Associate Professor

Chiang Mai University

View details

Yagai Bouba

Assistant Professor

Saint Camillus International University of Health Sciences

ITALY

View details

Andrew Owen

University of Liverpool

UNITED KINGDOM

View details

Chiara Minotti

University of Basel

SWITZERLAND

View details

Diana Gibb

Programme Leader

University College London

UNITED KINGDOM

View details

Seef Abdalla

Université Paris Cité

FRANCE

View details

Irene Mukui

University of Washington

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Marc Georges Jean Lallemant

Research Interests

Make your next move.

Articles (15)

Pharmacokinetic modeling to support WHO-weight band dosing of a new pediatric darunavir/ritonavir (120/20 mg) fixed-dose combination tablet for children at least 3 years old and weighing 10 to less than 35 kg

Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial.

Household SARS-CoV-2 transmission during Omicron wave in Chiang Mai, Thailand: a prospective observational study.

Effectiveness of community-based peer facilitated psychological and social support interventions on improving mental health in Cameroonian adolescents with perinatal HIV: the IAS-CIPHER-2021/1214-ATE SMAVI controlled randomized trial (November 2021-May 2023)

Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial.

Correction: Optimising Paediatric HIV Treatment: Recent Developments and Future Directions.

Single Doses of Pediatric Dolutegravir Dispersible Tablets in Neonates Support Multidosing: PETITE-Dolutegravir Study.

A community-based peer-facilitated psychological and social support model to improve retention in care among Cameroonian adolescents perinatally infected with human immunodeficiency virus: A randomized controlled trial.

Optimising Paediatric HIV Treatment: Recent Developments and Future Directions.

Impact of Human Immunodeficiency Virus Drug Resistance Mutations Detected in Women Prior to Antiretroviral Therapy With Efavirenz + Tenofovir Disoproxil Fumarate + Lamivudine (or Emtricitabine).

Association between mental disorders with detectable viral load and poor adherence to antiretroviral therapy among adolescents infected with Human Immunodeficiency Virus on follow-up at Chantal Biya Foundation, Cameroon.

Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial.

COVID-19 and MIS-C treatment in children—results from an international survey

Paediatric medicine issues and gaps from healthcare workers point of view: survey results and a narrative review from the global accelerator for paediatric formulations project

Novel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV.

Collaborators (7)

Ratchada Cressey

Yagai Bouba

Andrew Owen

Chiara Minotti

Diana Gibb

Seef Abdalla

Irene Mukui

Make your next move.